Polarean Imaging plc

Polarean did not report revenue or EPS for this presentation, but it said first-half revenue was disappointing and that no new systems were closed in the first half. Consumable growth was 36% for the first half of 2025 versus 2024. Cash at June 30 was about $7.3 million, with no debt, and management said the company is funded through Q2 2026. Full-year 2025 revenue guidance was revised to $2.5 million to $3.5 million from $5 million to $6 million, while management said it expects to return to $5 million to $6 million in 2026. Management also said the gas exchange Phase III trial has been redesigned to cost about $4 million to $4.5 million, down from prior expectations, and that the company believes it can reach profitability post-approval with around or a little less than $20 million in incremental investment.

Chris Von Jako framed the quarter as weak on revenue but said the underlying story remains intact: clinical demand, reimbursement, and scientific validation are all in place, while policy uncertainty has delayed hospital purchasing. He emphasized growing commercial momentum in quotes, pediatric access expansion, the new NIH order, and a pharma services vertical as strategic growth levers. His tone was candid about headwinds but optimistic that the company can move back to its prior revenue trajectory as budgets normalize and the gas exchange program advances.

Chuck Osborne emphasized disciplined spending, saying commercialization investments are being made carefully and that the company ended June with about $7.3 million in cash and no debt. He said consumable growth was 36% in the first half of 2025 versus 2024 and reiterated that cash funds the company through Q2 2026. He also confirmed the lowered 2025 revenue range of $2.5 million to $3.5 million, the expected 2026 return to $5 million to $6 million, and the view that profitability could follow gas exchange approval with around or a little less than $20 million in additional investment.

Analysts focused on the 36% consumable growth, the shift between systems and consumables, cash runway, the timing of the gas exchange trial, and whether Bracco and NUKEM would continue to support the company. Management said consumable growth is being driven by rising awareness, clinical and research usage, and new grants, while systems should still be the majority of sales over the next 18 months. On capital, management said the $7.3 million cash balance supports operations through Q2 2026, the gas exchange protocol is targeted to be finalized by year-end, and Bracco and NUKEM remain supportive partners. Questions also covered Medicaid/NIH funding pressure, international expansion, and pediatric reimbursement, with management saying uncertainty remains the main issue but China, Taiwan, and other Asia-Pacific markets look promising.